Centricity Vision Introduces New Name and Leadership Team

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Centricity Vision, Inc., formerly known as Mynosys Cellular Devices, Inc., a global ophthalmic technology company dedicated to delivering products that help surgeons optimize outcomes in refractive surgery, today announced a new executive leadership team, along with a new company name.

“Centricity Vision” reflects the company’s core competency, embodied by its ZEPTO® Precision Cataract Surgery Platform, in creating precise, consistent, visual axis-centered capsulotomies. The new name also conveys the company’s evolution as it looks to expand its vision care product pipeline beyond ZEPTO® while remaining committed to improving cataract surgery outcomes for surgeons and their patients.

In addition to Rob Thornhill’s recent appointment as Chief Executive Officer, new executive team members include Louis Bunn, Chief Financial Officer; Todd Pinkney, Vice President of Marketing; Kevin Pratt, Vice President of Sales; Dan Glazerman, Vice President of Research, Development and Manufacturing; and Nealen Hartman, Vice President of Regulatory Affairs and Quality Assurance. This seasoned team leverages extensive experience in the ophthalmology and medical device industries to drive technological innovation, product quality and commercial success.

The company’s ZEPTO® Platform enables precise, reproducible, circular, visual axis-centered capsulotomies that facilitate a 360-degree overlap of the IOL optic. Published studies demonstrate the ZEPTO® capsulotomy edge was two to four times stronger than manual CCC and femtosecond laser capsulotomy.1 ZEPTO® not only automates the anterior capsulotomy, but also enables precise visual axis centration.2

“We have evolved significantly as a company, and we think it’s time our name did too,” said Rob Thornhill, President and CEO of Centricity Vision. “Building on our commitment to assisting surgeons in delivering the best care to their patients, our vision for the future includes leveraging our ZEPTO® technology to create a suite of next-generation ophthalmic capsular management products. I’m grateful for the opportunity to work with our new management team to deliver high-quality systems to our customers and their patients.”


The ZEPTO® Precision Cataract Surgery Platform enables consistent, visual axis-centered, high-quality anterior capsulotomies during cataract surgery. ZEPTO® integrates seamlessly into the routine steps of cataract surgery without increasing operative time or space requirements. The ZEPTO® platform consists of a disposable handpiece and a small, inexpensive control console. The ZEPTO® precision pulse capsulotomy technology utilizes a proprietary energy control algorithm to deliver a four-millisecond energy pulse, in combination with calibrated suction, to produce highly accurate, reproducible and strong-edged capsulotomies. ZEPTO® performs equally as well in standard or difficult cases and is ideal for cataract patients choosing premium or non-premium lenses.

ZEPTO® is available directly through the company’s sales and practice support team in the United States, as well as through select distributors in Europe and Asia.



Subscribe to Medical Device News Magazine here.

Related Articles